Five Law Firms, Four Days, and the Securities Investigation Machine

Five different securities law firms announced "investigations" into AdaptHealth Corp. over the course of four days in early August 2026. SBS Law. The Law Offices of Frank R. Cruz. Glancy Prongay Wolke & Rotter. Howard G. Smith. Levi & Korsinsky. If you open their press releases side by side, they read like the same document with the letterhead changed. Each one quotes AdaptHealth's own earnings call — word for word — as evidence of potential securities fraud.

That is funny. The evidence of fraud that five law firms are independently "investigating" is the company telling investors what went wrong.

Here's what actually happened. On August 4, AdaptHealth reported second-quarter earnings before the market open. Revenue came in at $740 million, which was decent — 12.7% higher than the year-ago quarter. The problem was on the cost side. Cost of goods rose 22%, to $636 million, which is to say the company spent 85.9 cents of every revenue dollar on delivering its product, up from 79.3 cents the prior year. Operating margin flipped to negative 18.6%, from positive 9.9% in Q2 2025. Free cash flow turned negative, to minus $48 million year-to-date. Cash on hand dropped to $43 million. Debt is now $1.89 billion.

And then management did the thing that makes stocks go down: they cut full-year guidance. Adjusted EBITDA — earnings before interest, taxes, depreciation, and amortization, the cash-earnings proxy that matters most for a leveraged growth company — was slashed by $190 to $210 million, from a prior range of $680–$730 million down to $490–$520 million. Revenue guidance fell from $3.49 billion to roughly $2.87 billion.

The stock dropped 38% that day. It has since fallen further, trading around $5.69 as of early Friday, August 8. It is now roughly half the price it was in April, when it sat near $13.

And then the law firms showed up.

What these press releases are, at this stage, is lead generation. The word "investigation" in the name of a securities class action is not the same thing as a police investigation. Nobody has filed a complaint yet. Nobody has gathered evidence beyond the earnings release. What "investigation" means here is: we saw the stock drop more than 30%, we read the earnings press release, and we are now asking anyone who owns shares and is angry to submit their contact information so we can compete to become the lead lawyer in a future lawsuit.

The template is industrial-grade. Each press release contains the same numbers, the same quotes from the company, and the same assertion that a stock decline constitutes investor injury. This isn't lazy reporting. It's a business model. Securities class action firms operate on contingency — they get paid only if the case settles — so they need volume. The more investors they recruit into the pool, the more negotiating power they have, and the bigger their cut of the eventual settlement. The press release is a fishing line, cast the moment the stock moves enough to justify one.

For AdaptHealth shareholders, the joke is that this is the third time this has happened. The company has already paid out roughly $86 million across three separate settlements over the past five years.

The first securities class action (2019–2021 class period) settled for $51 million in cash plus 1 million shares. The allegations there were that AdaptHealth was miscounting its own organic growth — literally inflating the growth number by using a methodology that made acquisitions look like new business — and that the CEO was involved in an alleged foreign tax fraud from his private life.

The second securities class action (2020–2023 class period) settled for $35 million. This one was about billing practices and compliance: overcharging Medicare and Medicaid for diabetes equipment, submitting claims without proper documentation, altering doctors' prescriptions, shipping unnecessary medical equipment to patients, and gutting the compliance systems the company claimed it had built. The claim-filing deadline for that settlement was July 2, 2026. It was still open last month.

On top of that, in April 2023, AdaptHealth paid $5.3 million to resolve False Claims Act violations for allegedly submitting false claims to federal health care programs.

Now, four weeks after that second settlement's claims deadline closed, a new wave of law firms is asking investors to join a third "investigation." The trigger is the same familiar pattern: guidance that looked fine six weeks ago no longer looks fine today.

The actual mechanical problem this quarter is a West Coast capitated contract. Capitation is a payment model where a provider gets paid a fixed amount per patient per month, regardless of how much care that patient actually uses. It's the opposite of fee-for-service. The incentive is to keep patients healthy and costs low — if you can do that, you keep the difference. If you can't, you lose money on every patient.

AdaptHealth signed a big West Coast capitated deal. It was supposed to be the margin-expansion play: trade fee-for-service uncertainty for a stable per-patient revenue stream. Capitated revenue is now about $103 million, or roughly 14% of continuing revenue. The problem, disclosed in this quarter, is that the transition cost $55 million more than the company expected. That $55 million is a chunk of the $190–$210 million EBITDA guidance cut.

There's also a manufacturer price increase ($30 million hit), and the Diabetes Health business is being sold for $235 million, which reclassifies $100 million in revenue as discontinued operations and leaves $60 million of corporate overhead stranded in continuing ops.

The simplest model here is this: AdaptHealth is spending money to pivot from a high-margin fee-for-service model to a lower-margin capitated model, while simultaneously selling off the diabetes business that historically carried the most compliance risk (and presumably the most margin). The capitated model should be better in the long run — fewer billing disputes, fewer False Claims Act investigations, fewer securities class actions about compliance systems that don't exist. But the transition is expensive, and in the short run, costs rose faster than revenue.

The $144 million goodwill impairment that drove the GAAP loss is the accounting acknowledgment that some of the acquisitions AdaptHealth made to build its network are worth less than the company paid for them. That's not fraud. That's the mark-to-reality moment that happens when growth slows and integration proves harder than the deal memo assumed.

So what is the "fraud investigation" actually about? Nobody knows, because nobody has filed a complaint. But the pattern from the prior two class actions gives a rough template for what plaintiffs will eventually allege: that management was telling investors the capitated transition was under control, that cost growth was manageable, and that the guidance they carried into Q2 was honest, when in fact the company knew the West Coast deal was blowing through its budget.

That is the standard securities class action theory. The company said X. The company knew X was wrong or at risk. The stock fell when X turned out not to be true. Therefore, the company lied.

Whether that theory holds water in court depends on what management actually knew at the time of their prior statements, and whether there's evidence they concealed the capitated contract's cost overrun before the market learned about it. That's a discovery question, not a press-release question. The five law firms writing identical press releases haven't done discovery.

What they have done is set up a parallel income stream. If the case settles — and given that AdaptHealth has already settled two prior securities actions for a combined $86 million, the financial incentive to settle a third one exists — the lead lawyer gets a percentage of the fund. That percentage can be 15–30% of the settlement, minus administrative costs. On a $35 million settlement, that's $5 million to $10 million in legal fees.

AdaptHealth investors are caught between two things: a company that has an impressive track record of settling securities fraud claims, and an industry of lawyers whose business plan is to wait for the stock to drop and then ask to represent them.

The capitated contract is the real story. It's the mechanism that turned revenue growth into margin compression, and margin compression into a 40% stock decline, and a 40% stock decline into five identical press releases from lawyers who have never read AdaptHealth's 10-K but know exactly what to search for on Business Wire.

The simplest true story is that AdaptHealth made a bet on a payment model that shifts downside risk from insurer to provider, paid for it with debt, underestimated the transition cost, and now needs to sell a business unit to raise $235 million while lawyers queue up to sue over the guidance that made the bet look less risky than it was. The machine keeps running.